Health, with the receipts. Wellness Wire decodes the new science of human optimization — GLP-1s, peptides, longevity, and the science behind them.https://wellness-wire.com/en-us© Wellness Wirehttps://wellness-wire.com/articles/how-glp-1-medications-work/https://wellness-wire.com/articles/how-glp-1-medications-work/A plain-language look at what semaglutide, tirzepatide, and related drugs do inside the body, what the big trials showed, and where the science is still uncertain.Tue, 21 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/why-glp-1s-quiet-cravings/https://wellness-wire.com/articles/why-glp-1s-quiet-cravings/Semaglutide and tirzepatide do not run on willpower. Here is how they act on the brain circuits that create hunger — and what the neuroscience does, and does not yet, explain.Thu, 23 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/glp-1s-and-exercise-better-together/https://wellness-wire.com/articles/glp-1s-and-exercise-better-together/The biggest results do not come from the drug alone. Here is what the evidence says about pairing a GLP-1 with training — and why the combination beats either one by itself.Thu, 23 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/glp-1s-and-longevity/https://wellness-wire.com/articles/glp-1s-and-longevity/Strip away the number on the scale and these drugs still move things that matter more for how long you stay healthy. Here is the honest case — and the honest ceiling — for reading GLP-1s as a longevity story.Thu, 23 Jul 2026 00:00:00 GMTLongevityWellness Wire Editorialhttps://wellness-wire.com/articles/glp-1s-and-the-willpower-myth/https://wellness-wire.com/articles/glp-1s-and-the-willpower-myth/Obesity was framed for decades as a failure of discipline. The biology — and the drugs that act on it — tell a different story. Here is why "just eat less" was always the wrong advice.Thu, 23 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/semaglutide-weight-loss-evidence/https://wellness-wire.com/articles/semaglutide-weight-loss-evidence/A plain-language look at what the STEP trials — and the SELECT heart study — actually found about semaglutide (Wegovy) for weight loss: how much people lost, what happens when they stop, and where the evidence stops short.Mon, 20 Jul 2026 00:00:00 GMTSemaglutideWellness Wire Editorialhttps://wellness-wire.com/articles/tirzepatide-vs-semaglutide-evidence/https://wellness-wire.com/articles/tirzepatide-vs-semaglutide-evidence/Two weekly injections dominate the conversation about diabetes and obesity treatment. When they are compared directly, one tends to come out ahead on weight and blood sugar — but the fuller picture is more nuanced.Sun, 19 Jul 2026 00:00:00 GMTTirzepatideWellness Wire Editorialhttps://wellness-wire.com/articles/managing-glp-1-side-effects/https://wellness-wire.com/articles/managing-glp-1-side-effects/Nausea, diarrhea, vomiting, and constipation are the most common effects of semaglutide and tirzepatide. Here is what the trial evidence shows, and the practical steps experts recommend.Sat, 18 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/what-happens-when-you-stop-glp-1s/https://wellness-wire.com/articles/what-happens-when-you-stop-glp-1s/A plain-language look at what the research actually says about weight regain and fading health gains after stopping semaglutide or tirzepatide — and why researchers call it biology, not a personal failure.Fri, 17 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/glp-1s-and-muscle-mass/https://wellness-wire.com/articles/glp-1s-and-muscle-mass/GLP-1 medications like semaglutide and tirzepatide drive large weight loss. Some of what comes off is muscle-supporting tissue — here is what the evidence does, and doesn't, show.Thu, 16 Jul 2026 00:00:00 GMTMuscle & RecoveryWellness Wire Editorialhttps://wellness-wire.com/articles/semaglutide-heart-select-trial/https://wellness-wire.com/articles/semaglutide-heart-select-trial/The first trial to show a weight-loss drug can cut heart attacks and strokes, what the numbers really say, and who they apply to.Wed, 15 Jul 2026 00:00:00 GMTMetabolic HealthWellness Wire Editorialhttps://wellness-wire.com/articles/compounded-vs-brand-glp-1s/https://wellness-wire.com/articles/compounded-vs-brand-glp-1s/A plain-language guide to how compounded semaglutide and tirzepatide differ from their FDA-approved counterparts — in the evidence behind them, the oversight they get, and the risks they carry.Tue, 14 Jul 2026 00:00:00 GMTCompounded MedicineWellness Wire Editorialhttps://wellness-wire.com/articles/glp-1-dosing-and-titration/https://wellness-wire.com/articles/glp-1-dosing-and-titration/A plain-language look at why semaglutide and tirzepatide begin at doses too small to treat — and what the drug labels and clinical trials say about ramping up slowly.Mon, 13 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/tirzepatide-sleep-apnea-surmount-osa/https://wellness-wire.com/articles/tirzepatide-sleep-apnea-surmount-osa/The FDA's first-ever drug approval for obstructive sleep apnea rests on a trial called SURMOUNT-OSA. Here is what it showed, and what it did not.Sun, 12 Jul 2026 00:00:00 GMTTirzepatideWellness Wire Editorialhttps://wellness-wire.com/articles/who-is-a-candidate-for-glp-1s/https://wellness-wire.com/articles/who-is-a-candidate-for-glp-1s/A plain-language look at who fits the eligibility criteria for weight-management drugs like Wegovy and Zepbound — and who the labels say should not take them.Sat, 11 Jul 2026 00:00:00 GMTGLP-1Wellness Wire Editorialhttps://wellness-wire.com/articles/oral-vs-injectable-semaglutide/https://wellness-wire.com/articles/oral-vs-injectable-semaglutide/The same medicine now comes as a weekly shot or a daily pill. Here is what changes — and what stays the same — when you swap the needle for a tablet.Fri, 10 Jul 2026 00:00:00 GMTSemaglutideWellness Wire Editorialhttps://wellness-wire.com/articles/how-the-glp-1-telehealth-boom-happened/https://wellness-wire.com/articles/how-the-glp-1-telehealth-boom-happened/Blockbuster trial results, a $1,000-a-month price wall, and a drug-shortage loophole combined to move some of the most in-demand prescriptions in America onto telehealth websites — until the loophole closed.Thu, 09 Jul 2026 00:00:00 GMTThe Telehealth EconomyWellness Wire Editorialhttps://wellness-wire.com/articles/getting-a-glp-1-prescription-online/https://wellness-wire.com/articles/getting-a-glp-1-prescription-online/Telehealth companies now offer these weight-loss medicines after a short online form. Here is what FDA labeling, the major trials, and clinical guidelines actually say — and how to spot a risky service.Wed, 08 Jul 2026 00:00:00 GMTThe Telehealth EconomyWellness Wire Editorialhttps://wellness-wire.com/articles/the-end-of-the-glp-1-shortage/https://wellness-wire.com/articles/the-end-of-the-glp-1-shortage/The FDA says the shortages of the blockbuster weight-loss drugs are over. That decision reshapes who can legally make them, where the telehealth market goes next, and what is actually known about the copies.Tue, 07 Jul 2026 00:00:00 GMTThe Telehealth EconomyWellness Wire Editorialhttps://wellness-wire.com/articles/rapamycin-and-longevity-evidence/https://wellness-wire.com/articles/rapamycin-and-longevity-evidence/A drug that reliably extends lifespan in mice has become one of the most talked-about anti-aging compounds. Here is what has — and has not — been shown in people.Mon, 06 Jul 2026 00:00:00 GMTLongevityWellness Wire Editorialhttps://wellness-wire.com/articles/nad-boosters-and-aging/https://wellness-wire.com/articles/nad-boosters-and-aging/NAD+ boosters like NR and NMN reliably raise a number in your blood. Whether that slows aging is a much shakier claim than the marketing suggests.Sun, 05 Jul 2026 00:00:00 GMTLongevityWellness Wire Editorialhttps://wellness-wire.com/articles/biological-age-tests-explained/https://wellness-wire.com/articles/biological-age-tests-explained/Epigenetic clocks are a genuine scientific advance and a useful research tool — but the single "biological age" number a consumer test hands you comes with heavy caveats. Here's what the evidence actually supports.Sat, 04 Jul 2026 00:00:00 GMTLongevityWellness Wire Editorialhttps://wellness-wire.com/articles/what-peptide-therapy-actually-means/https://wellness-wire.com/articles/what-peptide-therapy-actually-means/The phrase covers everything from rigorously tested prescription drugs to compounds never completed in a single human trial. Here is how to tell them apart.Fri, 03 Jul 2026 00:00:00 GMTPeptidesWellness Wire Editorialhttps://wellness-wire.com/articles/pt-141-bremelanotide-evidence/https://wellness-wire.com/articles/pt-141-bremelanotide-evidence/Bremelanotide (Vyleesi) is FDA-approved for one specific group of women. The benefit is real but modest, nausea is common, and "PT-141" sold as a research peptide is a different story.Thu, 02 Jul 2026 00:00:00 GMTPeptidesWellness Wire Editorialhttps://wellness-wire.com/articles/bpc-157-what-the-evidence-shows/https://wellness-wire.com/articles/bpc-157-what-the-evidence-shows/The strong-sounding claims come almost entirely from rats and mice. Here is what has — and hasn't — actually been shown in people, and what regulators say.Wed, 01 Jul 2026 00:00:00 GMTPeptidesWellness Wire Editorial